
First-Line Acalabrutinib Plus BR Receives CHMP Recommendation for Mantle Cell Lymphoma
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of acalabrutinib (Calquence) in combination with bendamustine and rituximab (Rituxan; BR) for the …